Liver Cancer Trial, Recruiting NCT07119957 Sponsor: University Hospital, Angers Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT07119957
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a fatty liver disease related to metabolic causes, alcohol use, or a combination of both (known by terms such as MASLD, ALD, or MetALD)
  • People who have had a liver biopsy within the last 2 months, or who have one planned, either to confirm cirrhosis (scarring of the liver) without liver cancer (the "Control" group), or to confirm liver cancer on a cirrhotic liver (the "Case" group)
  • People who are covered by a social security or health insurance scheme in the relevant country
  • People who have read, understood, and signed a consent form agreeing to take part in the study, which involves the collection of biological samples

Who may not be able to join:

  • People whose liver disease is caused by something other than the conditions listed above (for example, viral hepatitis or autoimmune liver disease)
  • People who have had a serious liver-related complication in the two years before joining the study, such as fluid build-up in the abdomen, confusion caused by liver failure, bleeding from swollen veins in the digestive tract, liver failure, or kidney failure related to liver disease
  • People in the "Control" group who have a previous history of liver cancer
  • People who are currently pregnant, breastfeeding, or in labour
  • People who are currently detained or imprisoned by a legal or government decision

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jérôme BOURSIER, Professor, University Hospital, Angers

Phone: +33 (0)2 41 35 64 28

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Angers
Registry
ClinicalTrials.gov
Start date
17 December 2025
Est. completion
1 December 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Blood sample for biocollection; Urinary sample for biocollection; faecal sample for biocollection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov